Clinical trial
An Open-Label Extension Study of Continuing Treatment With Trofinetide for Rett Syndrome
Name
ACP-2566-005
Description
To investigate the safety and tolerability of continued long-term treatment with oral trofinetide in girls and women with Rett syndrome
Trial arms
Trial start
2020-11-08
Estimated PCD
2023-06-30
Trial end
2023-06-30
Status
Completed
Phase
Early phase I
Treatment
trofinetide
Study drug is administered twice a day for up to approximately 32 months. Doses may be taken orally or administered by gastrostomy (G) tube. The subject's assigned dose for this study will be the final dose from the antecedent study (ACP-2566-004).
Arms:
Drug - trofinetide
Size
78
Primary endpoint
Percentage of subjects with treatment-emergent adverse events (TAEs), percentage of subjects with serious adverse events (SAEs), and percentage of subjects withdrawals due to adverse events (AEs)
32 months
Number of subjects with post-Baseline potentially clinically important changes in ECG
32 months
Percentage of subjects with post-Baseline potentially clinically important changes in ECG
32 months
Number of subjects with post-Baseline potentially clinically important changes in vital signs
32 months
Percentage of subjects with post-Baseline potentially clinically important changes in vital signs
32 months
Number of subjects with post-Baseline potentially clinically important changes in body weight
32 months
Percentage of subjects with post-Baseline potentially clinically important changes in body weight
32 months
Number of subjects with post-Baseline potentially clinically important changes in laboratory parameters
32 months
Percentage of subjects with post-Baseline potentially clinically important changes in laboratory parameters
32 months
Eligibility criteria
Inclusion Criteria:
1. Has completed the EOT visit of the antecedent trofinetide Study ACP-2566-004 (i.e., has completed 40 weeks)
2. May benefit from continued treatment with open-label trofinetide in the judgment of the Investigator
3. Can still swallow the study medication provided as a liquid solution or can take it by gastrostomy tube
4. The subject's caregiver is English-speaking and has sufficient language skills to complete the caregiver assessments
Childbearing Potential
5. Subjects of childbearing potential must abstain from sexual activity for the duration of the study and for at least 30 days thereafter. If a subject is sexually active or becomes sexually active during the study, she must use 2 clinically acceptable methods of contraception (e.g., oral, intrauterine device \[IUD\], diaphragm plus spermicide, injectable, transdermal or implantable contraception) for the duration of the study and for at least 30 days thereafter. Subject must not be pregnant or breastfeeding.
Exclusion Criteria:
1. Began treatment with growth hormone during the antecedent study
2. Began treatment with IGF-1 during the antecedent study
3. Began treatment with insulin during the antecedent study
4. Has developed a clinically significant cardiovascular, endocrine (such as hypo- or hyperthyroidism, Type 1 diabetes mellitus, or uncontrolled Type 2 diabetes mellitus), renal, hepatic, respiratory, or gastrointestinal disease (such as celiac disease or inflammatory bowel disease)
5. Subject is judged by the Investigator or the Medical Monitor to be inappropriate for the study due to AEs, medical condition, or noncompliance with investigational product or study procedures in the antecedent study
6. Has a clinically significant abnormality in vital signs at Baseline
7. Has an average QTcF interval of \>450 ms on the Baseline ECG performed before the first dose of trofinetide is given in the present study (i.e., the ECG performed at the EOT visit of the antecedent study)
8. Has developed a clinically significant ECG finding during the antecedent study
Additional inclusion/exclusion criteria apply. Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically, if it is determined that their baseline health and condition do not meet all pre-specified entry criteria).
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 78, 'type': 'ACTUAL'}}
Updated at
2023-08-01
1 organization
Organization
Acadia Pharmaceuticals Inc.